Rating Change
Morgan Stanley reiterated its Overweight rating on Charles River Laboratories International, Inc. (NYSE:CRL) on October 13, 2026.
reiterateNYSE:CRL
Morgan Stanley Reiterates Overweight Rating on Charles River Laboratories International, Inc. (CRL)
Morgan Stanley reiterated its Overweight rating on Charles River Laboratories International, Inc. (NYSE:CRL) on October 13, 2026.
At publication ·
What changed
Charles River Laboratories International, Inc. (NYSE:CRL) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $299.02
- Market capitalization
- $9.6B
At a glance
Key takeaways
- Morgan Stanley reiterated an Overweight rating on Charles River Laboratories on October 13, 2026, with the stock trading at $299.02.
- CRL has gained 46.8% over the past 52 weeks and has a market capitalization of $9.6 billion.
- Among the 10 most recent analyst ratings, 9 were Buy or Overweight and 1 was Hold, with no Sell ratings.
- Analyst ratings are one input among many for investment decisions and have mixed predictive power on their own.
Market Context
Charles River Laboratories International, Inc. operates in the Healthcare sector. The stock currently trades at $299.02 with a market capitalization of $9.6B. The stock has gained 46.8% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Charles River Laboratories International, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Charles River Laboratories International, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Overweight | N/A |
| Sep 30, 2026 | UBS | Buy | N/A |
| Sep 28, 2026 | Jefferies | Buy | N/A |
| Sep 25, 2026 | Deutsche Bank | Buy | N/A |
| Sep 25, 2026 | Evercore ISI Group | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CRL Stock Page
Frequently Asked Questions
What does the Overweight rating mean for CRL?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Charles River Laboratories International, Inc. (NYSE:CRL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CRL forecast page.
Loading related coverage…
